Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway

Neuropharmacology

Volumn 76, Issue PART A, 2014, Pages 137-145

  Fukuyama, Kouji ^a   Tanahashi, Shunske ^a   Hoshikawa, Masamitsu ^b   Shinagawa, Rika ^b   Okada, Motohiro ^a  

^a MIE UNIVERSITY   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Astrocyte; Cinnabarinic acid; Kynurenine pathway; Parkinson's disease; Xanthurenic acid; Zonisamide

Indexed keywords

GAMMA INTERFERON; KYNURENIC ACID; KYNURENINE; LEVODOPA; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; QUINOLINIC ACID; TUMOR NECROSIS FACTOR ALPHA; XANTHURENIC ACID; ZONISAMIDE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BASAL GANGLION; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME RELEASE; GLOBUS PALLIDUS; LIQUID CHROMATOGRAPHY; MACROGLIA; MALE; MASS SPECTROMETRY; MICRODIALYSIS; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; SIGNAL TRANSDUCTION; SUBTHALAMUS;

ASTROCYTE; CINNABARINIC ACID; KYNURENINE PATHWAY; PARKINSON'S DISEASE; XANTHURENIC ACID; ZONISAMIDE;

ANIMALS; ASTROCYTES; BASAL GANGLIA; DRUG INTERACTIONS; INTERFERON-GAMMA; KYNURENINE; NEURAL PATHWAYS; PRIMARY CELL CULTURE; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886533107     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.08.002     Document Type: Article

References (44)

1. S.P. Alexander, A. Mathie, and J.A. Peters Guide to Receptors and Channels (GRAC), 5th edition Br. J. Pharmacol. 164 Suppl. 1 2011 S1 S324
2. M. Asanuma, I. Miyazaki, F.J. Diaz-Corrales, N. Kimoto, Y. Kikkawa, M. Takeshima, K. Miyoshi, and M. Murata Neuroprotective effects of zonisamide target astrocyte Ann. Neurol. 67 2010 239 249
3. L. Asp, A.S. Johansson, A. Mann, B. Owe-Larsson, E.M. Urbanska, T. Kocki, M. Kegel, G. Engberg, G.B. Lundkvist, and H. Karlsson Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts J. Inflamm. (Lond) 8 2011 25
4. P.E. Bermejo Zonisamide in patients with essential tremor and Parkinson's disease Mov Disord. 22 2007 2137 2138
5. G. Boka, P. Anglade, D. Wallach, F. Javoy-Agid, Y. Agid, and E.C. Hirsch Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease Neurosci. Lett. 172 1994 151 154 (Pubitemid 24178765)
6. M.A. Cenci Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia Trends Neurosci. 30 2007 236 243 (Pubitemid 46654236)
7. P. Chakrabarty, C. Ceballos-Diaz, W.L. Lin, A. Beccard, K. Jansen-West, N.R. McFarland, C. Janus, D. Dickson, P. Das, and T.E. Golde Interferon-gamma induces progressive nigrostriatal degeneration and basal ganglia calcification Nat. Neurosci. 14 2011 694 696
8. C.S. Copeland, S.A. Neale, and T.E. Salt Actions of Xanthurenic Acid, a putative endogenous Group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus Neuropharmacology 66 2013 133 142
9. R.J. Dobbs, A. Charlett, A.G. Purkiss, S.M. Dobbs, C. Weller, and D.W. Peterson Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism Acta Neurol. Scand. 100 1999 34 41 (Pubitemid 29292549)
10. S. Duty Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease Br. J. Pharmacol. 161 2010 271 287
11. C.L. Eastman, T.R. Guilarte, and J.R. Lever Uptake of 3-hydroxykynurenine measured in rat brain slices and in a neuronal cell line Brain Res. 584 1992 110 116
12. F. Fazio, L. Lionetto, G. Molinaro, H.O. Bertrand, F. Acher, R.T. Ngomba, S. Notartomaso, M. Curini, O. Rosati, P. Scarselli, R. Di Marco, G. Battaglia, V. Bruno, M. Simmaco, J.P. Pin, F. Nicoletti, and C. Goudet Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors Mol. Pharmacol. 81 2012 643 656
13. T.C. Frank-Cannon, L.T. Alto, F.E. McAlpine, and M.G. Tansey Does neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegener. 4 2009 47
14. G.J. Guillemin, S.J. Kerr, G.A. Smythe, D.G. Smith, V. Kapoor, P.J. Armati, J. Croitoru, and B.J. Brew Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection J. Neurochem. 78 2001 842 853 (Pubitemid 32777985)
15. G.J. Guillemin, D.G. Smith, G.A. Smythe, P.J. Armati, and B.J. Brew Expression of the kynurenine pathway enzymes in human microglia and macrophages Adv. Exp. Med. Biol. 527 2003 105 112 (Pubitemid 38197634)
16. S. Hunot, F. Boissiere, B. Faucheux, B. Brugg, A. Mouatt-Prigent, Y. Agid, and E.C. Hirsch Nitric oxide synthase and neuronal vulnerability in Parkinson's disease Neuroscience 72 1996 355 363 (Pubitemid 26111202)
17. S.L. McElroy, T. Suppes, P.E. Keck Jr., D. Black, M.A. Frye, L.L. Altshuler, W.A. Nolen, R.W. Kupka, G.S. Leverich, J. Walden, H. Grunze, and R.M. Post Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial J. Clin. Psychiatry 66 2005 617 624 (Pubitemid 40733705)
18. J.C. McGrath, G.B. Drummond, E.M. McLachlan, C. Kilkenny, and C.L. Wainwright Guidelines for reporting experiments involving animals: the ARRIVE guidelines Br. J. Pharmacol. 160 2010 1573 1576
19. M. Mogi, T. Kondo, Y. Mizuno, and T. Nagatsu p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain Neurosci. Lett. 414 2007 94 97 (Pubitemid 46241643)
20. V. Montana, E.B. Malarkey, C. Verderio, M. Matteoli, and V. Parpura Vesicular transmitter release from astrocytes Glia 54 2006 700 715 (Pubitemid 44629633)
21. M. Murata Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease Curr. Pharm. Des. 10 2004 687 693 (Pubitemid 38292396)
22. M. Murata, K. Hasegawa, and I. Kanazawa Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study Neurology 68 2007 45 50 (Pubitemid 46058551)
23. M. Nakagawa, S. Yamamura, E. Motomura, T. Shiroyama, H. Tanii, and M. Okada Combination therapy of zonisamide with aripiprazole on ECT- and benzodiazepine-resistant periodic catatonia J. Neuropsychiatry Clin. Neurosci. 24 2012 E9
24. F. Nicoletti, J. Bockaert, G.L. Collingridge, P.J. Conn, F. Ferraguti, D.D. Schoepp, J.T. Wroblewski, and J.P. Pin Metabotropic glutamate receptors: from the workbench to the bedside Neuropharmacology 60 2011 1017 1041
25. T. Ogawa, W.R. Matson, M.F. Beal, R.H. Myers, E.D. Bird, P. Milbury, and S. Saso Kynurenine pathway abnormalities in Parkinson's disease Neurology 42 1992 1702 1706
26. 2+ dependent dopamine release Epilepsy Res. 13 1992 113 119
27. M. Okada, S. Kaneko, T. Hirano, K. Mizuno, T. Kondo, K. Otani, and Y. Fukushima Effects of zonisamide on dopaminergic system Epilepsy Res. 22 1995 193 205
28. G. Paxinos, and C. Watson The Rat Brain: in Stereotoxic Coordinates 1998 Academic Press San Dieg
29. M.A. Rogawski, and R.J. Porter Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds Pharmacol. Rev. 42 1990 223 286 (Pubitemid 20291784)
30. R. Schwarcz, J.P. Bruno, P.J. Muchowski, and H.Q. Wu Kynurenines in the mammalian brain: when physiology meets pathology Nat. Rev. Neurosci. 13 2012 465 477
31. M. Seino, and I. Leppik Zonisamide J. Engel Jr. T.A. Pedley, Epilepsy: a Comprehensive Text Book vol. 2 2007 Lippincott Williams & Wilkins Philadelphia 1695 1701
32. T.W. Stone Kynurenines in the CNS: from endogenous obscurity to therapeutic importance Prog. Neurobiol. 64 2001 185 218 (Pubitemid 32195412)
33. S. Suzuki, K. Kawakami, S. Nishimura, Y. Watanabe, K. Yagi, M. Seino, and K. Miyamoto Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex Epilepsy Res. 12 1992 21 27
34. O. Taleb, M. Maammar, D. Brumaru, J.J. Bourguignon, M. Schmitt, C. Klein, V. Kemmel, M. Maitre, and A.G. Mensah-Nyagan Xanthurenic acid binds to neuronal G-protein-coupled receptors that secondarily activate cationic channels in the cell line NCB-20 PloS One 7 2012 e48553
35. S. Tanahashi, S. Yamamura, M. Nakagawa, E. Motomura, and M. Okada Clozapine, but not haloperidol, enhances glial d-serine and l-glutamate release in rat frontal cortex and primary cultured astrocytes Br. J. Pharmacol. 165 2012 1543 1555
36. A. Toulouse, and A.M. Sullivan Progress in Parkinson's disease-where do we stand? Prog. Neurobiol. 85 2008 376 392
37. L.J. Willmore Zonisamide overview of the United States experience Seizure 13 Suppl. 1 2004 S57 S58
38. S. Yamamura, M. Hoshikawa, D. Kato, H. Saito, N. Suzuki, O. Niwa, and M. Okada ONO-2506 inhibits spike-wave discharges in a genetic animal model without affecting traditional convulsive tests via gliotransmission regulation Br. J. Pharmacol. 2013 1088 1100
39. S. Yamamura, K. Ohoyama, H. Nagase, and M. Okada Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway Neuropharmacology 57 2009 322 331
40. S. Yoshida, M. Okada, G. Zhu, and S. Kaneko Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors Epilepsy Res. 67 2005 153 162 (Pubitemid 41676824)
41. S. Yoshida, M. Okada, G. Zhu, and S. Kaneko Carbamazepine prevents breakdown of neurotransmitter release induced by hyperactivation of ryanodine receptor Neuropharmacology 52 2007 1538 1546 (Pubitemid 46678087)
42. 2+ signaling and caspase-3 activity in neuronal PC12 cells Cell Mol. Neurobiol. 33 2013 205 212
43. D. Zadori, P. Klivenyi, J. Toldi, F. Fulop, and L. Vecsei Kynurenines in Parkinson's disease: therapeutic perspectives J. Neural Transm. 119 2012 275 283
44. A. Zinger, C. Barcia, M.T. Herrero, and G.J. Guillemin The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease Parkinsons Dis. 2011 2011 716859